Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
22:01:28 EDT Sun 19 May 2024
Enter Symbol
or Name
USA
CA



Q:VRNA - VERONA PHARMA SPON ADR EACH REP 8 ORD SHS - https://www.veronapharma.com/
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
VRNA - Q0.112.12·14.920.113.00-0.36-2.71,161.914,8198,20713.42  13.50  12.9723.07  11.8316:58:02May 0915 min RT 2¢

Recent Trades - Last 10 of 8207
Time ETExPriceChangeVolume
16:58:02Q13.00-0.3610,828
16:00:03Q13.00-0.364,638
16:00:03Q13.00-0.36100
16:00:03Q13.00-0.362,635
16:00:01Q13.00-0.36209
16:00:00Q13.00-0.3661
16:00:00Q13.00-0.3661
16:00:00Q13.00-0.3661
16:00:00Q13.00-0.36108
16:00:00Q13.00-0.36224

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-05-09 07:15U:VRNANews ReleaseVerona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update
2024-05-09 07:00U:VRNANews ReleaseVerona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS
2024-05-02 02:00U:VRNANews ReleaseVerona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024
2024-04-25 02:00U:VRNANews ReleaseVerona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update
2024-03-04 02:00U:VRNANews ReleaseAndrew Fisher Joins Verona Pharma as General Counsel
2024-02-29 02:00U:VRNANews ReleaseVerona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
2024-02-15 02:00U:VRNANews ReleaseVerona Pharma to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update
2024-02-01 02:00U:VRNANews ReleaseMichael Austwick Joins Verona Pharma as Non-Executive Director
2024-01-03 02:00U:VRNANews ReleaseVerona Pharma to Present at 42nd Annual J.P. Morgan Healthcare Conference
2024-01-02 02:00U:VRNANews ReleaseVerona Pharma enters into Debt Facility of up to $400 Million with Oxford Finance and Hercules Capital
2023-11-17 02:00U:VRNANews ReleaseVerona Pharma ¢ € ™s President and CEO David Zaccardelli Wins Executive of the Year SCRIP Award
2023-11-08 02:00U:VRNANews ReleaseVerona Pharma Announces November 2023 Investor Conference Participation
2023-11-02 03:04U:VRNANews ReleaseVerona Pharma Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2023-10-19 02:00U:VRNANews ReleaseVerona Pharma to Report Third Quarter 2023 Financial Results and Provide Corporate Update
2023-10-06 02:00U:VRNANews ReleaseVerona Pharma to Host Investor Update on Commercialization Preparation for Ensifentrine on October 18, 2023
2023-10-03 02:00U:VRNANews ReleaseVerona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at CHEST 2023
2023-09-11 02:00U:VRNANews ReleaseVerona Pharma Announces the US FDA has Accepted the New Drug Application Filing for Ensifentrine for the Maintenance Treatment of COPD
2023-09-06 02:00U:VRNANews ReleaseVerona Pharma to Present Additional Analysis of Phase 3 ENHANCE-1 Study in COPD at ERS International Congress 2023
2023-08-31 02:00U:VRNANews ReleaseChristina Ackermann Joins Verona Pharma as ‚  Non-Executive Director
2023-08-03 02:00U:VRNANews ReleaseVerona Pharma Reports Second Quarter 2023 Financial Results and Provides Corporate Update